Your session is about to expire
← Back to Search
Mesenchymal Stem Cell
Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome
Phase 1 & 2
Waitlist Available
Led By Amanda Olson
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at day 30 post msc infusion
Awards & highlights
No Placebo-Only Group
Summary
This trial will test whether it is feasible to use cord blood-derived mesenchymal stem cells (MSCs) to treat patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection. If it is successful, a larger trial will be conducted to compare the effect of MSCs with standard of care in these patients.
Eligible Conditions
- COVID-19
- Blood Cancers
- COVID-19 Infection
- Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at day 30 post msc infusion
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at day 30 post msc infusion
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of composite serious adverse events (Phase I)
Secondary study objectives
Clinical parameters (Phase I)
Incidence of infusion-related adverse events (Phase I)
Laboratory markers (Phase I)
+7 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Pilot study (mesenchymal stem cells)Experimental Treatment1 Intervention
Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion.
Group II: Phase II Arm I (mesenchymal stem cells)Experimental Treatment1 Intervention
Patients receive MSCs as in the Pilot study.
Group III: Phase II Arm II (standard of care)Active Control1 Intervention
Patients receive standard of care.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,074 Previous Clinical Trials
1,803,277 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,112,017 Total Patients Enrolled
2 Trials studying Blood Cancers
112 Patients Enrolled for Blood Cancers
Amanda OlsonPrincipal InvestigatorM.D. Anderson Cancer Center
4 Previous Clinical Trials
185 Total Patients Enrolled